Zhengye Biotechnology COO files initial ownership

Zhengye Biotechnology Holding Ltd filed an initial ownership report for Chief Operating Officer Liu Zhongyao.

Accepted by SEC EDGAR 03/18/2026 - 04:10 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Zhengye Biotechnology Holding Ltd filed an initial ownership report for Chief Operating Officer Liu Zhongyao. This Form 3 filing identifies Liu as an executive officer of the company but does not show any share purchases, sales, exercises, gifts, or other transactions in the data provided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Zhengye Biotechnology (ZYBT) Form 3 filing report for Liu Zhongyao?

The Form 3 filing reports that Liu Zhongyao is the Chief Operating Officer of Zhengye Biotechnology Holding Ltd. It serves as an initial ownership report, without detailing any specific share transactions in the provided data.

Does the ZYBT Form 3 show Liu Zhongyao buying or selling any shares?

No, the provided Form 3 data for ZYBT shows no recorded purchases or sales by Liu Zhongyao. The transaction summary lists zero buy, sell, exercise, gift, tax withholding, or restructuring transactions.

What is Liu Zhongyao’s role at Zhengye Biotechnology (ZYBT) according to this filing?

According to the filing, Liu Zhongyao is an officer of Zhengye Biotechnology Holding Ltd and holds the title of Chief Operating Officer. The report classifies him as an executive but does not provide specific share counts.

Why is a Form 3 important for Zhengye Biotechnology (ZYBT) investors?

Form 3 identifies insiders like executives or major owners at ZYBT. This filing confirms Liu Zhongyao as Chief Operating Officer and sets a baseline for future insider reports, even though no actual transactions are shown in the provided data.

Are there any derivative securities reported for Liu Zhongyao in the ZYBT Form 3?

No derivative securities are shown for Liu Zhongyao in the provided data. The derivative summary is empty and the transaction summary lists zero derivative transactions or option exercises related to Zhengye Biotechnology Holding Ltd.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Liu Zhongyao

(Last) (First) (Middle)

NO.1 LIANMENG ROAD

(Street)

JILIN CITY, JILIN PROVINCE 132101

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Zhengye Biotechnology Holding Ltd [ ZYBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Zhongyao Liu	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)